Volver al Panel





Amgen Inc. (AMGN)
Valores intradiarios en tiempo real
Resumen del Mercado
From:
To:
AMGN Intraday
No data available
SímboloAMGN
Fecha de SalidaJun 17, 1983
CEOMr. Robert A. Bradway
Empleados a Tiempo Completo31.5k
SectorHealthcare
IndustriaDrug Manufacturers - General
PaísUnited States
BolsaNasdaqGS
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Rendimiento
| Período | Rentabilidad % | Cambio de Valor |
|---|---|---|
| 1 Día | -0.63% | -2.77 US$ |
| 5 Días | -6.36% | -29.62 US$ |
| 1 Mes | -0.52% | -2.29 US$ |
| 6 Meses | +28.51% | +96.75 US$ |
Analizando el Mercado con IA
Evaluando los últimos 30 días de historial y métricas fundamentales de AMGN...
Estadísticas Clave
Cap. de Mercado
235.64B
Relación P/E
25.25
Rend. de Div.
2.30%
Máx. 52 Semanas
$483.99
Mín. 52 Semanas
$312.39
Consenso de Analistas
CONSENSOMantener
ALCISTA1132.4%
NEUTRAL1852.9%
BAJISTA514.7%
Objetivos de Precios de Analistas a 52 Semanas
Objetivo Mín.
$230.00
$230.00
Objetivo Máx.
$542.00
$542.00
Actual$436.05
Objetivo Prom.$437.01
Recomendaciones de Analistas
Precio Objetivo:$437.01($230.00 - $542.00)
¿Buscas más valores? Explóralos en el screener
Pensamientos de la Comunidad
Comparta su análisis y sentimiento sobre AMGN
Únase a la comunidad para compartir su análisis
Últimas Noticias para AMGN
Mizuho Adjusts Price Target on Amgen to $388 From $352, Maintains Neutral Rating
MT Newswires•20 nov 2026, 15:14

Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Zacks•20 nov 2026, 13:00
What SPDR Dow Jones Industrial Avg ETF (DIA) Bought: Goldman Leads on Nov. 18
GuruFocus.com•20 nov 2026, 11:03
Amgen Inc's Dividend Analysis
GuruFocus.com•20 nov 2026, 10:01
Securitize Adds Anthropic to Tokenized Stock Platform
MT Newswires•19 nov 2026, 18:25

Viridian Therapeutics initiated at 'buy' by Bank of America with $47 price target
Proactive•19 nov 2026, 17:48
Viridian Therapeutics' Lumvoa Emerging as Rival to Amgen's Tepezza, BofA Securities Says
MT Newswires•19 nov 2026, 16:02

Eli Lilly Stopped Touting Dose Counts. Should You Worry?
Trefis•19 nov 2026, 15:09

Amgen (AMGN) Has Advanced MariTide Into Phase 3 Trials
Simply Wall St.•19 nov 2026, 14:19

Should You Buy Exelixis Stock For Its Cash?
Trefis•19 nov 2026, 11:43